SCHEMBL25073205

SCHEMBL25073205

O=C(O)c1cnc(NS(=O)(=O)c2cnc(-c3ccc(F)cc3)s2)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 4/20 0.45
▸ CSNK2A2 P19784 3/20 0.44
▸ CSNK2A1 P68400 3/20 0.44
▸ PTPN11 Q06124 1/20 0.43
▸ HDAC3 O15379 3/20 0.38
▸ HDAC2 Q92769 3/20 0.38
▸ HDAC6 Q9UBN7 3/20 0.38
▸ HDAC8 Q9BY41 2/20 0.38
▸ XDH P47989 1/20 0.38
▸ HDAC4 P56524 1/20 0.38
▸ HDAC7 Q8WUI4 1/20 0.38
▸ HDAC10 Q969S8 1/20 0.38
▸ HDAC11 Q96DB2 1/20 0.38
▸ HDAC9 Q9UKV0 1/20 0.38
▸ HDAC5 Q9UQL6 1/20 0.38
▸ BCL2L1 Q07817 1/20 0.38
▸ BAD Q92934 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25073254 0.86 CSNK2A2 (0.46) HDAC1CSNK2A2CSNK2A1PTPN11BCL2L1
SCHEMBL25072408 0.86 PTPN11 (0.51) CSNK2A2CSNK2A1PTPN11BCL2L1BAD
SCHEMBL25072757 0.84 PTPN11 (0.41) HDAC1CSNK2A2CSNK2A1PTPN11HDAC3
SCHEMBL25073028 0.82 PTPN11 (0.44) HDAC1CSNK2A2CSNK2A1PTPN11HDAC3
SCHEMBL25073309 0.82 THRB (0.43) HDAC1CSNK2A2CSNK2A1PTPN11HDAC3
SCHEMBL25073318 0.82 PFKFB3 (0.53) PTPN11KMT2A
SCHEMBL25073247 0.81 CXCR4 (0.46) CSNK2A2CSNK2A1PTPN11BCL2L1BAD
SCHEMBL25072760 0.81 KDM4E (0.47) HDAC1CSNK2A2CSNK2A1PTPN11HDAC3
SCHEMBL25073200 0.81 PTPN11 (0.43) HDAC1CSNK2A2CSNK2A1PTPN11HDAC3
SCHEMBL30278475 0.80 PTPN11 (0.46) HDAC1CSNK2A2CSNK2A1PTPN11HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 HDAC1 574/4885CSNK2A2 1475/4885CSNK2A1 1240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback